Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs Abatacept (Primary) ; Ciclosporin; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Acronyms Aba NMD
- 05 Nov 2018 Planned End Date changed from 1 Jan 2020 to 29 Sep 2019.
- 05 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 29 Sep 2019.
- 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.